Could first anti-tau therapy be approved for Alzheimer’s?
The oral medication Hydromethylthionine mesylate (HMTM) is the first anti-tau disease-modifying therapy to offer sustained cognitive improvement in Alzheimer’s.
List view / Grid view
The oral medication Hydromethylthionine mesylate (HMTM) is the first anti-tau disease-modifying therapy to offer sustained cognitive improvement in Alzheimer’s.
In a Phase IIb trial, hospitalised COVID-19 patients treated with desidustat did not develop acute respiratory distress syndrome (ARDS).
In hospitalised COVID-19 patients, researchers found that C21 reduced the risk of needing oxygen at the end of treatment by 40 percent.
Direct eye injections treat uveitic macular edema more effectively than treatments placed adjacent to the eye, reveals new Mount Sinai research...
The FDA has heard from professional groups, including the American Academy of Paediatrics about the use of opioid cough suppressants for children...
21 July 2016 | By Niamh Louise Marriott, Digitial Content Producer
Almost $3 million in funding to support a Phase II trial of a new therapeutic approach, developed by Amylyx, for the treatment of ALS...